Conference abstract · 31 Mar 2017
Conference abstractPublished 31 Mar 2017
Different structure-oriented design of selective butyrylcholinesterase probe and its application in drug discovery
Central China Normal University, China
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
The two major human cholinesterases are acetylcholinesterase (AChE; EC 3.1.1.7) and butyrylcholinesterase (BChE; EC 3.1.1.8), and are very important enzymes in multiple areas such as pharmacology, neurobiology and toxicology due to their significant roles in human body and health. Although the biological function is uncertain, the BChE levels have been implicated in lipid metabolism and various human diseases such as liver damage, cirrhosis, AlzheimerâÂ?Â?s disease (AD) and liver metastasis. BChE is also responsible for detoxifying xenobiotics like organophosphates and cocaine and is a well-known biomarker for clinical diagnosis. Thus, the quantification of BChE activity and its inhibition is not only important in diseases diagnosis, but also indispensable for drug discovery. We report on the different structure-oriented design and application of a selective fluorogenic molecular probe (BChEFP) for human butyrylcholinesterase (BChE). This probe, rationally designed by mimicking the native substrate and manipulating the steric feature of the recognition group of designed probes targeting the structural difference of the active sites for BChE and acetylcholinesterase (AChE), exhibits near-zero background fluorescence but produce remarkable fluorescence enhancement upon the catalysis by BChE in a fast biochemical reaction. To the best of our knowledge, BChE-FP is the first probe that can discriminate BChE from AChE, which is successfully applied for BChE inhibitor screening and characterization under physiological conditions, and BChE detection in human serum. These results demonstrate that this molecular probe can function as a useful molecular tool for high-throughput drug discovery against BChE-related diseases, as well as the biosensing for neuromuscular blocking agents.
Ask about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
Similar by topic
Conference abstract · 9 Dec 2015
Genome to future drug discovery and design in cancer and infectious disease
Conference abstract · 6 Jan 2016
A combined structure and ligand based approach to design novel, selective PDE4b inhibitors
Conference abstract · 5 Dec 2015
High-quality domain-based protein interaction mapping: application for drug discovery
Research article · 2016
An Approach to Computer Aided Drug Design of some Bioactive Cinnamoyl Hydrazones, In Silico and Docking Studies as Possible COX-2 Selective Inhibitors
More from this journal
The newest in Journal of Biotechnology & Biomaterials.
Editorial · 30 May 2025
Biocatalytic Conversion of Agricultural Waste into Value-Added Chemicals Using Engineered Microbial Systems
Editorial · 30 May 2025
3D Bioprinting of Vascularized Tissue Constructs Using Bioink-Embedded Endothelial Cells
Editorial · 30 May 2025
Development of Flexible Bioelectronic Interfaces for Real-Time Neural Signal Monitoring
Conferences in this field
Upcoming conferences in this field.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalJournal of Biotechnology & Biomaterials
- SubjectBiochemistry & Biotechnology
- SubjectMaterials Science
- BylineArticles whose byline prints “Wen-Chao Yang”
- BylineArticles whose byline prints “Shu-Hou Yang”
- BylineArticles whose byline prints “Qi Sun”
- BylineArticles whose byline prints “Guang-Fu Yang”
